Figure 6.

Meclofenamate-mediated sensitizing effects are accompanied by reduced Aurora kinase A expression and elevated programmed cell death pathway signaling. (A) Workflow illustration. After cells were treated with CCNU and the combination of CCNU and MFA for 48 h, RNA sequencing was performed. (B) Venn diagram depicting the number of differentially expressed genes of G6 and G32 cell populations separately and the number of shared differentially expressed genes. (C) Volcano plot of differentially expressed genes in CCNU monotreatment vs. combination treatment. (D) Barplot of AURKA expression. (E) Western blot analysis and densitometric quantification of AURKA protein expression. (F,G) Gene Set Enrichment Analysis of MSigDM REACTOME_MAPK_Family_Signaling_Cascades Pathway. (F) and REACTOME_Programmed_Cell_Death Pathway. (G) CCNU monotreatment compared to the untreated control is marked in black whereas CCNU monotreatment compared to combination treatment with MFA is marked in red. AURKA, Aurora kinase A; CCNU, lomustine; MFA, meclofenamate.